Form 4: X4 Pharmaceuticals Director Gary Bridger Acquires 45,000 Shares in Annual Award

Director Gary Bridger acquired 45,000 shares of X4 Pharmaceuticals as part of an annual award for board service.

Summary

• Gary Bridger, a director at X4 Pharmaceuticals, acquired 45,000 shares of common stock on June 10, 2024.
• The acquisition was an annual award for service on the Board of Directors.
• These shares were granted as restricted stock units (RSUs) at a price of $0.
• The RSUs will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the Issuer's next annual meeting of stockholders, subject to continued board service through the applicable vesting date.
• Bridger now beneficially owns 96,667 shares of X4 Pharmaceuticals.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The acquisition of shares by a director is generally viewed as a positive sign, indicating confidence in the company. However, it's a routine transaction related to compensation.

Positives

• The acquisition of shares by a director can be seen as a positive sign, indicating confidence in the company's future.

Future Outlook

The RSUs will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the Issuer's next annual meeting of stockholders, subject to continued board service through the applicable vesting date. The RSUs will vest in full upon the occurrence of a change in control of the Issuer.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the actions of company insiders, such as directors and officers, regarding their company's stock.

Stakeholder Impact

• The acquisition of shares by a director could have a slightly positive impact on shareholder sentiment.

Key Dates